Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leucine/metformin/sildenafil - NuSirt Biopharma

Drug Profile

Leucine/metformin/sildenafil - NuSirt Biopharma

Alternative Names: Leu-Met-Sil; Leucine/sildenafil/metformin; Metformin/leucine/sildenafil; Metformin/sildenafil/leucine; NS-0200; Sildenafil/leucine/metformin; Sildenafil/metformin/leucine

Latest Information Update: 30 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NuSirt Biopharma
  • Class Biguanides; Branched-chain amino acids; Essential amino acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; SIRT1 protein stimulants; Sirtuin modulators; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-alcoholic fatty liver disease
  • No development reported Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 30 Nov 2022 No development reported - Phase-II for Obesity in USA (PO)
  • 28 Jun 2019 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
  • 17 Aug 2018 NuSirt Biopharma completes a phase II trial in Obesity in USA (PO) (NCT03364335)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top